NZ716669B2 - Multiple myeloma treatment - Google Patents
Multiple myeloma treatment Download PDFInfo
- Publication number
- NZ716669B2 NZ716669B2 NZ716669A NZ71666914A NZ716669B2 NZ 716669 B2 NZ716669 B2 NZ 716669B2 NZ 716669 A NZ716669 A NZ 716669A NZ 71666914 A NZ71666914 A NZ 71666914A NZ 716669 B2 NZ716669 B2 NZ 716669B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- tsa
- day
- human
- genes
- aurkb
- Prior art date
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims abstract description 26
- 201000009251 multiple myeloma Diseases 0.000 title claims abstract description 10
- RTKIYFITIVXBLE-QEQCGCAPSA-N Trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims abstract description 32
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 16
- 102100007326 BIRC5 Human genes 0.000 claims description 10
- 102100003215 CCNB1 Human genes 0.000 claims description 10
- 102100011985 KIF2C Human genes 0.000 claims description 10
- 101700016152 KIF2C Proteins 0.000 claims description 10
- 102100011938 TOP2A Human genes 0.000 claims description 10
- 101700084031 TOP2A Proteins 0.000 claims description 10
- 101700006955 CCNB1 Proteins 0.000 claims description 9
- 108010002687 Survivin Proteins 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 8
- 101700069373 KIF11 Proteins 0.000 claims description 7
- 102100017012 KIF11 Human genes 0.000 claims description 7
- 108060006684 WEE1 Proteins 0.000 claims description 7
- 102100002579 WEE1 Human genes 0.000 claims description 7
- 210000002966 Serum Anatomy 0.000 claims description 6
- 238000001962 electrophoresis Methods 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 210000002700 Urine Anatomy 0.000 claims description 4
- 210000001185 Bone Marrow Anatomy 0.000 claims description 3
- 101700051654 CDK1 Proteins 0.000 claims description 3
- 238000002441 X-ray diffraction Methods 0.000 claims description 3
- 238000004166 bioassay Methods 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 2
- 101700037792 AURKB Proteins 0.000 claims 3
- 102100010553 AURKB Human genes 0.000 claims 3
- 101710018449 CKS1B Proteins 0.000 claims 3
- 102100001226 CKS1B Human genes 0.000 claims 3
- 102100017064 ASPM Human genes 0.000 claims 2
- 101700006766 ASPM Proteins 0.000 claims 2
- 101700048555 CDK2 Proteins 0.000 claims 2
- 101710022231 CDK2AP1 Proteins 0.000 claims 2
- 101710040092 POLD1 Proteins 0.000 claims 2
- 102100012348 POLD1 Human genes 0.000 claims 2
- 101700023985 pol3 Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004228 Aurora Kinase B Human genes 0.000 description 10
- 108090000749 Aurora Kinase B Proteins 0.000 description 10
- -1 ASPM Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 102000003964 Histone deacetylases Human genes 0.000 description 3
- 108090000353 Histone deacetylases Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940068917 Polyethylene Glycols Drugs 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 101700054568 BIRC5 Proteins 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010060385 Cyclin B1 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 102000018358 Immunoglobulins Human genes 0.000 description 1
- 108060003951 Immunoglobulins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 210000004011 Plasma Cells Anatomy 0.000 description 1
- 229960004063 Propylene glycol Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Description
MULTIPLE A TREATMENT
CROSS-REFERENCE TO D APPLICATIONS
This application claims the benefit of co-pending US Provisional Patent Application
Nos. 61/869,039, filed 22 August 2013 and 61/870,747, filed 27 August 2013, each ofwhich is
incorporated .
BACKGROUND
le myeloma (MM), sometimes referred to as plasma cell myeloma, is a
multifocal plasma cell cancer of the osseous system, lly affecting elderly individuals.
Most individuals are matic when sed, with diagnosis typically made by one or
more of serum protein electrophoresis, serum free kappa/lambda light chain assay, urine
protein electrophoresis (99% of patients with MM exhibit increased levels of one of the
immunoglobulin (Ig) classes in the blood and/or light chains in the urine), bone marrow
examination, or X-ray analysis. Although MM generally responds to chemotherapy,
recurrence is common, since such treatment does not target cancer stem cells.
Nara et al. have recently identified a number of candidate genes for targeting MM
tumor-initiating subpopulation (SP) cells, i.e., cancer stem cells. These include a number of
genes coding for ns associated with cell cycle and mitosis, all of which were found to be
upregulated in MM cells. These include cyclin B1 (CCNBl), cell division cycle 2 (CDC2),
baculoviral IAP repeat-containing 5 (BIRCS), abnormal spindle homolog, microcephaly-
associated (ASPM), omerase (DNA) II alpha 170kDa (TOP2A), aurora kinase B
(AURKB), kinesin family member 11 (KIF11), and kinesin family member 2c (KIF2C).
Similarly, Shaughnessy et al. report a 70-gene high-risk profile for multiple myeloma.
Two of the genes upregulated in this high-risk profile are CDC28 protein kinase tory
subunit 1B (CKS1B) and WEEl homolog (S. pombe) (WEEl).
SUMMARY
One embodiment of the invention provides a method of treating multiple myeloma
(MM) in an individual, the method comprising: administering to the individual an effective
amount of trichostatin A (TSA).
In another embodiment, the invention provides a method of treating multiple myeloma
(MM) in an individual, the method comprising: determining, from a biological sample
obtained from the individual’s body, a level of expression of at least one gene selected from a
group ting of: CCNB l, AURKB, CDC2, BIRCS, KIFl l, KIFZC, TOP2A, ASPM,
CKSlB, and WEEl; and in the case that the level of sion of the at least one gene is
indicative of overexpression, administering to the individual an effective amount of
trichostatin A (TSA).
In yet another embodiment, the invention provides a method of treating multiple
myeloma (MM) in an individual, the method comprising: diagnosing or having diagnosed the
dual with MM; and administering to the individual an effective amount of trichostatin A
(TSA).
In still yet another embodiment, the invention provides a pharmaceutical composition
sing: trichostatin A (TSA) as a sole or primary inhibitor of CCNBl, AURKB, CDC2,
BIRCS, KIFl l, KIFZC, TOP2A, ASPM, CKSlB, or WEEl; and a ceutically-
acceptable ent or carrier.
In still other embodiments of the invention, treatment with TSA is combined with one
or more other multiple myeloma treatments. Such other treatments may include, for e,
small le inhibition.
DETAILED DESCRIPTION
Trichostatin A (TSA or 7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl
oxohepta-2,4-dienamide), is an antifiangal antibiotic. The structure of TSA is shown in
Formula I below.
Formula I
Applicants have surprisingly found that TSA, although previously known as a class I
and II histone deacetylase (HDAC) inhibitor, is also capable of ting expression of
CCNBl, AURKB, CDC2, BIRCS, KIF l l, KIF2C, TOP2A, ASPM, CKS 1B, and WEEl.
Accordingly, TSA may be used as a primary or sole inhibitor of one or more such genes in the
treatment of MM.
A human retinal pigment epithelial cell line was treated with statin or vehicle for
24 hours and gene expression for 22,238 probe sets covering 12,490 genes was generated
using an Affymetrix instrument. The effect of trichostatin A on sion of CCNB l ,
AURKB, CDC2, BIRCS, KIFl l, KIF2C, TOP2A, ASPM, CKSlB, and WEEl is shown below
in Table l, and indicates significant downregulation of the expression of each gene.
Table 1
Instance ID Probe Rank Fold Expression A Gene
42 219918_s_at 22283 -69.97232079 ASPM
10005533 219918_s_at 22282 -54.61735261 ASPM
10005532 219918_s_at 22261 -23.24977266 ASPM
10005542 209464_at 22190 -11.52858083 AURKB
10005533 209464_at 22185 -11.04347695 AURKB
10005542 202095_s_at 22270 -24.2000252 BIRC5
10005533 202095_s_at 22256 -23.02258123 BIRC5
10005533 202094_at 22251 -20.743 85736 BIRC5
10005532 202095_s_at 22252 -19.95557418 BIRC5
10005542 202094_at 22227 -14.71770993 BIRC5
10005532 _at 22219 -14.42912247 BIRC5
10005533 214710_s_at 22267 -26.45555632 CCNB1
10005532 214710_s_at 22267 -26.32053821 CCNB1
10005542 214710_s_at 22251 -20.15506664 CCNB1
10005532 203213_at 22270 -27. 14720991 CDC2
10005533 203213_at 22260 -23.81235655 CDC2
10005542 203213_at 22253 -20.26528442 CDC2
10005533 210559_s_at 22199 -12.07146825 CDC2
10005532 210559_s_at 22192 -11.92448867 CDC2
10005533 203214_x_at 22194 -11.8262682 CDC2
10005542 204444_at 22213 -13.12379506 KIF11
10005532 204444_at 22187 -11.4579544 KIF11
10005533 204444_at 22184 -10.96422696 KIF11
10005533 209408_at 22250 -19.89427497 KIF2C
10005532 209408_at 22248 -19.35105571 KIF2C
10005542 209408_at 22224 -14.47328923 KIF2C
10005532 201292_at 22274 62153 TOP2A
10005533 201291_s_at 22270 -28.21627346 TOP2A
10005532 201897_s_at 22279 584911 CKS 1B
10005533 201897_s_at 22279 -52.93016044 CKS 1B
10005542 201897_s_at 22268 -23.90194858 CKS 1B
10005532 212533_at 22237 -17.0758281 WEE1
10005533 212533_at 22248 -19.46663938 WEE1
42 _at 22265 -23.63054187 WEE1
These results support the use of TSA in the treatment of MM. For example, an
individual may be treated for MM by administering to the individual an effective amount of
TSA, wherein the effective amount is an amount sufficient to t sion of one or more
of CCNB1, AURKB, CDC2, BIRC5, KIFl 1, KIF2C, TOP2A, ASPM, CKSlB, and WEE1 in
the individual. Such an amount may also be sufficient to t HDAC ty in the
individual. In some ments of the invention, the effective amount is between about 0.01
WO 27125
mg/kg/day and about 100 mg/kg/day, e. g., n about 0.1 mg/kg/day and about 10
mg/kg/day or between about 0.5 mg/kg/day and about 5 mg/kg/day.
In some embodiments, treating the individual may further comprise determining, from
a biological sample obtained from the individual’s body, a level of expression of one or more
of CCNBl, AURKB, CDC2, BIRCS, KIFl l, KIFZC, TOPZA, ASPM, CKSlB, or WEEl.
Such determining may include any known or later-developed method or technique, including,
for example, quantitative antigen—antibody interactions, the use of labeled nucleotide probes,
etc.
In other embodiments of the invention, treating the individual may e sing
or having diagnosed the individual with MM prior to stering TSA to the individual.
Such diagnosing may include one or more technique or method for making such a diagnosis,
including, for example, serum n electrophoresis, serum free kappa/lambda light chain
assay, urine protein electrophoresis, bone marrow examination, or X-ray analysis.
TSA may be administered to the individual to be treated in the form of a
pharmaceutical composition. Pharmaceutical compositions to be used according to various
embodiments of the invention comprise a therapeutically effective amount of TSA or an active
metabolite of TSA, or a pharmaceutically acceptable salt or other form (e.g., a solvate) thereof,
er with one or more pharmaceutically acceptable ents or carriers. The phrase
“pharmaceutical composition” refers to a composition suitable for administration in medical
use. It should be appreciated that the determinations of proper dosage forms, dosage amounts,
and routes of administration for a particular patient are within the level of ordinary skill in the
pharmaceutical and medical arts.
Administration may be oral but other routes of administration may also be employed,
e. g., parenteral, nasal, buccal, ermal, sublingual, intramuscular, enous, rectal,
vaginal, etc. Solid dosage forms for oral administration include capsules, tablets, pills,
powders, and granules. In such solid dosage forms, the compound is admixed with at least one
inert pharmaceutically-acceptable excipient such as (a) fillers or extenders, as for example,
starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) s, as for e,
carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, (c)
humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium
carbonate, (e) solution retarders, as for e paraffin, (f) absorption accelerators, as for
example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol,
and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, and (i)
lubricants, as for e, talc, m te, magnesium stearate, solid polyethylene
glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills,
the dosage forms may also comprise buffering agents. Solid dosage forms such as tablets,
drages, capsules, pills, and es also can be prepared with gs and shells, such as
enteric coatings and others well known in the art. The solid dosage form also may contain
opacifying agents, and can also be of such composition that they release the active compound
or compounds in a certain part of the intestinal tract in a delayed manner. Examples of
embedding compositions which can be used are polymeric substances and waxes. The active
compounds can also be in micro-encapsulated form, if appropriate, with one or more of the
mentioned excipients. Such solid dosage forms may generally contain from 1% to 95%
(w/w) of the active compound. In certain embodiments, the active nd ranges from 5%
to 70% (w/w).
Solid compositions for oral administration can be formulated in a unit dosage form,
each dosage containing from about 0.1 mg to about 5000 mg of active ingredient. The term
“unit dosage form” refers to physically te units suitable as unitary dosages for human
subjects and other mammals, each unit containing a predetermined quantity of active
ingredient calculated to produce the desired effect over the course of a treatment period, in
association with the required pharmaceutical r. TSA can be formulated, e.g., in a unit
dosage form that is a capsule having 0.1—5000 mg of active in addition to ents.
Liquid dosage forms for oral administration include pharmaceutically-acceptable
ons, solutions, suspensions, syrups, and elixirs. In addition to the compound or
composition, the liquid dosage forms may contain inert diluents commonly used in the art,
such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl
l, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propyleneglycol, l,3-butyleneglycol, ylformamide, oils, in particular, cottonseed oil,
groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofilrfilryl
alcohol, polyethyleneglycols and fatty acid esters of sorbitan or mixtures of these substances.
Besides such inert diluents, the composition can also include adjuvants, such as wetting agents,
fying and suspending agents, sweetening, flavoring, and perfilming agents.
In some embodiments of the invention, TSA is provided in a liquid form and
administered to an individual intravenously. According to some embodiments of the
invention, TSA is ed in a sustained or controlled e formulation.
While this ion has been described in conjunction with the specific ments
outlined above, it is evident that many alternatives, modifications and variations will be
apparent to those skilled in the art or are otherwise intended to be ed. Accordingly, the
embodiments of the invention as set forth above are intended to be illustrative, not limiting.
Various changes may be made without departing from the spirit and scope of the invention as
defined in the following claims. All patents, patent application, scientific articles and other
published documents cited herein are hereby incorporated in their entirety for the substance of
their disclosures.
Claims (5)
1. Use of trichostatin A (TSA) in the manufacture of a medicament for the treatment of multiple myeloma (MM) in a human, the treatment comprising: determination, from a biological sample obtained from the human’s body, of a level of sion of one or more genes in the human, the one or more genes selected from a group consisting of: CCNB1, AURKB, CDC2, BIRC5, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1; and in the case that the level of expression of the one or more genes is indicative of overexpression, administration to the human of an amount of TSA effective to decrease the level of expression of the one or more genes.
2. The use according to claim 1, wherein the amount of TSA decreases the level of sion of: a) either or both of CCNB1 and AURKB; b) either or both of CKS1B and WEE1; or c) each of CCNB1, AURKB, CDC2, BIRC5, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1.
3. The use according to claim 1, wherein the amount of TSA is between about 0.01 mg/kg/day and about 100 mg/kg/day or between about 0.1 mg/kg/day and about 10 mg/kg/day or between about 0.5 mg/kg/day and about 5 mg/kg/day.
4. The use according to claim 1, wherein the administration of TSA is oral or intravenous.
5. The use according to claim 1, wherein the treatment further comprises: diagnosis of, or having diagnosed the human using at least one diagnostic test selected from a group consisting of: serum protein electrophoresis, serum free kappa/lambda light chain assay, urine protein electrophoresis, bone marrow ation, and X-ray analysis.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361869039P | 2013-08-22 | 2013-08-22 | |
US61/869,039 | 2013-08-22 | ||
US201361870747P | 2013-08-27 | 2013-08-27 | |
US61/870,747 | 2013-08-27 | ||
PCT/US2014/052216 WO2015027125A1 (en) | 2013-08-22 | 2014-08-22 | Multiple myeloma treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ716669A NZ716669A (en) | 2021-03-26 |
NZ716669B2 true NZ716669B2 (en) | 2021-06-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11737993B2 (en) | Multiple myeloma treatment | |
US20230355580A1 (en) | Methods of improving renal function | |
US20240052418A1 (en) | Method for predicting a subject's response to slc modulator therapy | |
Moreno et al. | Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors | |
KR20170069262A (en) | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide | |
JP2021105005A (en) | Cancer treatment | |
US9301947B2 (en) | Ryanodine receptor inhibitors for treatment of T-cell mediated disorders | |
NZ716669B2 (en) | Multiple myeloma treatment | |
KR20180120565A (en) | Method of providing the information for selecting the drugs for treating EML4-ALK positive non-small-cell lung cancer resistant to ALK inhibitors | |
JP2023513552A (en) | Combination therapies and biomarkers for treating B-cell lymphoma | |
US20220304979A1 (en) | Methods of reducing disease flares | |
Kienast et al. | PS978 DISCOVERY OF NOVEL C/D BOX SNORNAS THAT ARE REQUIRED FOR LEUKEMIA CELL PROLIFERATION |